# Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

> **NCT00454363** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (actual)

## Conditions studied

- Gastrin-Producing Neuroendocrine Tumor
- Lung Carcinoid Tumor
- Metastatic Digestive System Neuroendocrine Tumor G1
- Multiple Endocrine Neoplasia Type 1
- Pancreatic Glucagonoma
- Pancreatic Insulinoma
- Pancreatic Polypeptide Tumor
- Recurrent Digestive System Neuroendocrine Tumor G1
- Recurrent Pancreatic Neuroendocrine Carcinoma
- Regional Digestive System Neuroendocrine Tumor G1
- Somatostatin-Producing Neuroendocrine Tumor

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pazopanib Hydrochloride
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00454363
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454363, "Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00454363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*